Drug discovery doesnt fail at the end. It fails at the start.
Most R&D teams dont realize theyre running a late-stage race until theyve already missed the turn: the moment you finally check the patents after lead selection, after target validatio…

Bioequivalence is the easy part. Freedom to operate is the cliff.
For years, the industrys success checklist for generics and biosimilars has looked deceptively simple: show bioequivalence, win the market, move on. In reality, bioequivalence is often t…

The Safe Patent Portfolio Trap: Why Minimal Filing Costs Are Quietly Rewriting Pharmas Growth Curve
Pharma has a new favorite phrase: build a safe patent portfolio. It sounds prudentdefensive, risk-managed, portfolio-lite. But behind the language of mi…

A $50 million notice letter didnt just failit revealed how a single paragraph can cost a generic company real time, real money, and real leverage.
Heres the part many people miss: Paragraph IV litigation isnt only about whether a patent is valid. Its a…

At-Risk Launches: When The Math Says Go Beats The Court Says No
In the world of pharma, timing isnt just strategyits leverage. And nowhere is that more visible than in the controversial calculus behind at-risk launches: launching a product before paten…

Patent litigation isnt just about winningits about preventing expensive downstream loss.
That sounds obvious, but in pharma, its often ignored until its too late.
Consider the hidden ROI of an early challenge to a weak method-of-use drug patentthe ki…

The 180-Day Exclusivity Trap: Why First-to-File Winners Still Lose Money
In drug development, there are moments when the calendar looks like a promise. One of the biggest: 180-day exclusivity for certain first filers under the Hatch-Waxman framework. I…

A lot of pharma litigation strategy is built on a comforting myth: Well just settle.
That mindset feels pragmaticuntil you run the math. If youre making decisions based on vibes, youre effectively betting your future on outcomes you dont control. And…